Dissecting the IL-6 pathway in cardiometabolic disease: A Mendelian randomization study on both IL6 and IL6R.

Arjen J Cupido Folkert W. Asselbergs Pradeep Natarajannull nullPaul M Ridker G Kees Kornelis Hovingh Amand Floriaan Schmidt

Published in: British journal of clinical pharmacology (2022)

IL-6 signalling perturbation by either IL6 or IL6R genetic instruments is associated with a similar risk reduction for multiple cardiometabolic diseases, suggesting that both IL-6 and IL-6R are potential therapeutic targets to lower CVD. Moreover, IL-6 rather than IL-6R inhibition might have a more favourable pneumonia risk.

Keyphrases

gene expression
human health